Chairpersons: A. Tufail UK, M. Zinkernagel SWITZERLAND, A. Gaudric FRANCE, JR Vingerling THE NETHERLANDS
M. Zinkernagel SWITZERLAND
Are we able to predict reactivation after therapy cessation in patients with neovascular AMD
S. Vujosevic ITALY
What to do with a DME which does not dry after 6 months of continuous anti-VEGF treatment
Should we operate on lamellar macular holes?
Should we do PRP when stopping anti-VEGF treatment for CMO related to ischemic CRVO? OR Is it safe to use artificial intelligence algorithms to manage retina patients?
A. Tufail UK
Should we inject a quiescent CNV in a fellow eye of a treated neovascular AMD patient?
JR Vingerling THE NETHERLANDS
Should we induce CNV in AMD to protect from atrophy?
R. Dolz Marco SPAIN
Why is it important to differentiate myopic choroidal neovascularisation from idiopathic multifocal choroiditis, or punctuate inner choroidopathy?
Y. Ikuno JAPAN
Should we operate myopic foveoschisis with significant macular thickening before vision drop
M. Tedja THE NETHERLANDS
Should we treat young children with myopia?